A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-rearranged Non-Small Cell Lung Cancer

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-rearranged Non-Small Cell Lung Cancer

The identification of oncogenic driver driver mutations in non-small cell lung cancer has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4-ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is...

Full description

Bibliographic Details
Main Authors: Khashayar eEsfahani, Jason Scott Agulnik, Victor eCohen
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-07-01
Series:Frontiers in Oncology
Subjects:
Clinical Trials as Topic
anaplastic lymphoma kinase (ALK)
crizotinib
Non small cell lung cancer
driver mutations
ALK inhibitors
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00174/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00174/full

Similar Items